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Abstract The effects of antidepressants on the gastroin-
testinal tract may contribute to their potential efficacy in
functional dyspepsia and irritable bowel syndrome;
buspirone, a prototype 5-HT1A agonist, enhances gastric
accommodation and reduces postprandial symptoms in
response to a challenge meal. Paroxetine, a selective
serotonin reuptake inhibitor, accelerates small bowel but
not colonic transit, and this property may not be relevant to
improve gut function in functional gastrointestinal disor-
ders. Venlafaxine, a prototype serotonin norepinephrine
reuptake inhibitor, enhances gastric accommodation,
increases colonic compliance and reduces sensations to
distension; however, it is associated with adverse effects
that reduce its applicability in treatment of functional
gastrointestinal disorders. Tricyclic antidepressants reduce
sensations in response to food, including nausea, and delay
gastric emptying, especially in females. Buspirone appears
efficacious in functional dyspepsia; amitriptyline was not
efficacious in a large trial of children with functional gas-
trointestinal disorders. Clinical trials of antidepressants for
treatment of irritable bowel syndrome are generally small.
The recommendations of efficacy and number needed to
treat from meta-analyses are suspect, and more prospective
trials are needed in patients without diagnosed psychiatric
diseases. Antidepressants appear to be more effective in the
treatment of patients with anxiety or depression, but larger
prospective trials assessing both clinical and pharmacody-
namic effects on gut sensorimotor function are needed.
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Introduction
Irritable bowel syndrome (IBS) is a multifactorial disorder
in which psychosocial aspects interact with altered func-
tioning to cause a disorder with high clinical and societal
impact. A pivotal neurotransmitter mediating central and
peripheral dysfunction is serotonin (5-HT). Serotonin is an
important neurotransmitter in both the brain and gastroin-
testinal tract, where it plays a key role in the regulation of
sensory and motor functions.
Serotonergic receptors and the reuptake of serotonin
modify the effects of the neurotransmitter. This is exemplified
by the variation in the reuptake of serotonin through genetic
variations in the uptake process. 5-HT transporter (SERT, also
called SLC6A4) is central to fine-tuning brain 5-HT neuro-
transmission and is abundant in cortical and limbic areas,
thereby affecting emotional aspects of behavior, the occur-
rence of anxiety, and other psychiatric disease. Variation in
the promoter region upstream of the 5-HT coding sequence
(SERT-P) or promoter is manifest as long polymorphic
region (5HTTLPR) and short variants of the region impact
the response to antidepressant treatment [1]. In addition,
5-HTTLPR genotype (s allele) is associated with higher pain
sensory ratings during rectal distension in health and IBS [2],
and 5-HTTLPR (s/s genotype) activates greater regional
cerebral blood flow in specific brain regions (left anterior
cingulate cortex and right parahippocampal gyrus) in response
to 0–40 mmHg colorectal distention in humans [3].
Serotonergic psychoactive agents are frequently used
in treatment of patients with functional gastrointestinal
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disorders (FGIDs). The central effects of these agents are
well established; however, there are also gastrointestinal
effects of these agents. The objectives of this paper are to
review the pharmacodynamic effects of these agents on
gastrointestinal functions, and to examine how these effects
might be reflected in results of randomized, controlled
trials with these agents.
Serotonergic psychoactive agents
and pharmacodynamics in functional dyspepsia
The Rome III criteria for functional dyspepsia are as
follows [4].
Patients must have had one or more of the following
symptoms for the past 3 months, with symptom onset at
least 6 months prior to diagnosis: postprandial fullness,
early satiety, epigastric burning, as well as no evidence of
structural disease that is likely to explain symptoms
(including any condition detected by upper endoscopy).
This is further classified as:
(A) Postprandial distress syndrome
(B) Epigastric pain syndrome
In general, the pathophysiology of functional dyspepsia
involves psychosocial factors, altered motility (including
gastric emptying and accommodation) and altered sensation;
a subset of patients reports a prior episode of gastroenteritis.
Among serotonergic psychoactive agents proposed for
treatment of functional dyspepsia, buspirone, a 5-HT1A
receptor agonist, enhanced gastric relaxation [5], and par-
oxetine, a selective serotonin reuptake inhibitor (SSRI,
30 mg paroxetine daily for 4 days), accelerated orocecal
transit in 10 healthy controls and 8 IBS patients, but there
was no effect on whole gut transit time [6, 7].
There is a third class of combined serotonin and
norepinephrine reuptake inhibitors (SNRI), of which a
prototype is venlafaxine. In a detailed study of upper
gastrointestinal functions (gastric emptying accommoda-
tion and satiation) in healthy participants [8], the effects of
a spectrum of serotonergic psychoactive agents adminis-
tered (at standard starting doses to treat anxiety and
depression) for 11 days showed that paroxetine, 20 mg per
day, accelerated orocecal transit of a solid meal; buspirone,
10 mg p.o. twice daily, decreased postprandial aggregate
symptom and nausea scores after a fully satiating liquid
nutrient meal; and venlafaxine-XR, 75 mg per day,
enhanced gastric accommodation measured by SPECT
imaging, a validated method to measure gastric volume
[9, 10]. These data suggest a potential for use of buspirone
and venlafaxine in functional dyspepsia.
Has this been translated into efficacious treatment in
patients with functional dyspepsia? Tack et al. examined
the effects of buspirone on gastric functions and post-
prandial symptoms in 17 patients with functional dyspepsia
in a double-blind, placebo-controlled, randomized trial.
The study showed reduction in fullness, bloating, belching,
and nausea, as well as overall dyspepsia severity score, and
this was associated with increased postprandial accom-
modation, but there were no significant effects on gastric
emptying or sensation thresholds in response to balloon
distension in the stomach [11].
On the other hand, the effects of venlafaxine, 75–150
mg, compared to placebo were tested in functional
dyspepsia, but this treatment was associated with con-
siderable drop-outs secondary to adverse events (such
as nausea, palpitations, sweating, sleeping disorders,
dizziness, visual impairment), and no overall clinical
efficacy was demonstrated during treatment or follow-up
[12].
The effects of the tricyclic antidepressant (TCA), ami-
triptyline, on postprandial symptoms were tested in healthy
volunteers and in patients with functional dyspepsia. In
healthy volunteers, amitriptyline retards gastric emptying
and reduces postprandial (caloric drink challenge) symp-
toms, especially nausea [13]. A single-center, parallel-
group study showed amitriptyline (12.5–50 mg for
8 weeks), compared to placebo, did not affect drinking
capacity and postprandial symptoms evoked by the drink
test in 38 functional dyspepsia patients. However, during
the entire treatment, nausea symptom score was signifi-
cantly reduced by amitriptyline compared with placebo
[14]. Results of an NIH-funded multicenter study of clin-
ical efficacy are awaited [15]. Meanwhile, a small study
from Japan compared amitriptyline to no treatment in
patients with functional dyspepsia who were famotidine
and mosapride non-responders. Significant benefits were
observed in the amitriptyline groups [16]. On the other
hand, a large multicenter study of amitriptyline in children
with diverse FGIDs showed no benefit of the TCA over
placebo [17].
Serotonergic psychoactive agents
and pharmacodynamics in irritable bowel syndrome
The Rome III diagnostic criteria for IBS [18] are as
follows:
Recurrent abdominal pain or discomfort at least 3 days
per month in the last 3 months associated with 2 or more of
the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance)
of stool
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In general, the pathophysiology of IBS involves
psychosocial factors, altered motor function (including
motility and transit), altered sensation, and altered host
genetic and intraluminal factor interactions [19, 20]. Many
patients report a prior episode of gastroenteritis.
In a detailed study of lower gastrointestinal functions
(colonic motility, compliance and sensation) in healthy
participants [21], buspirone had virtually no effects,
whereas venlafaxine increased compliance, relaxed tone,
reduced postprandial colonic contraction, and tended to
increase thresholds for sensation of first perception and
gas, while it also reduced pain sensation ratings in
response to grades distensions. Both buspirone and ven-
lafaxine did not significantly alter colonic transit in
healthy participants [8].
The main effect of the SSRI, fluoxetine (20 mg a day for
6 weeks), was to reduce pain scores, especially in non-
depressed IBS patients who were hypersensitive at baseline
before drug administration, but no differences were seen in
rectal sensation in the overall group [22].
Another SSRI, citalopram, was tested first in healthy
volunteers. Acute citalopram infusion increased colonic
contractility, including induction of high amplitude prop-
agated contractions, reduced colonic tone during fasting,
as well as reduced the increase in tone after meal inges-
tion. While citalopram increased colonic compliance, it
had no significant effect on sensation [23]. In a separate,
small cross-over, randomized, controlled trial of 23
patients with IBS, Tack et al. [24] showed efficacy of
citalopram in pain, bloating and overall symptom scores.
These effects were independent of anxiety, depression, and
colonic sensorimotor function. On the other hand, in a
slightly smaller study, Talley et al. [25] showed no benefit
with citalopram on global IBS endpoints over placebo. In
a large, multicenter, parallel- group, randomized, con-
trolled trial, both paroxetine and psychotherapy improved
health-related quality of life in severe IBS without any
additional costs [26]. In another placebo controlled trial of
IBS patients, refractory to high-fiber diet, paroxetine
improved overall well-being, but no improvement was
seen in abdominal pain, bloating, or social functioning
[27]. Another small study examining effects of fluoxetine
in Rome II IBS-C patients showed decrease in abdominal
discomfort, bloating, and improvements in stool frequency
and consistency [28]. No study has examined the efficacy
of mirtazapine in symptoms or sensorimotor function
in IBS.
An interesting animal study highlights difficulty in
correlating antinociceptive effects of drugs with different
antidepressant classes across a range of neuropathic pain
models, and suggests that antidepressants with both
noradrenaline and 5-HT action might have more potent
antinociceptive effects than SSRIs [29].
Efficacy of serotonergic psychoactive agents
in meta-analyses in irritable bowel syndrome
The American College of Gastroenterology Task Force
Report of 2009 suggested there are several effective
treatments for IBS, such as fiber, peppermint oil, antide-
pressants, probiotics, and antispasmodics/smooth muscle
relaxants. Indeed, the estimated number needed to treat was
as low as 4 for many classes of treatment, including anti-
depressants [30]. Other meta-analyses reached different
conclusions. There is always concern when meta-analyses
include trials with different designs, different doses, diverse
mechanisms, and small trials to reach conclusions that are
often proposed in societal guidelines. It is wise to follow the
counsel that meta-analyses should only be used for
hypothesis generation [31]. Moreover, when multiple
treatment comparison meta-analyses use indirect evidence
from randomized controlled trials to compare the relative
effectiveness of all included interventions, they are partic-
ularly vulnerable to potential biases that can affect the
interpretation of these analyses [32]. In fact, several sys-
tematic analyses have been published and reach different
conclusions, and it is not surprising when one considers the
different data sets that are included within each meta-
analysis, whether they are commissioned by national soci-
eties [33], individual research groups [34], or the Cochrane
Systematic reviews [35]. These illustrate different conclu-
sions on the efficacy of antidepressants in IBS treatment.
Three specific studies included in many of these meta-
analyses illustrate the dangers of these analyses based on the
unrepresentative nature of the results, or the use of secondary
endpoints in individual trials that are used in drawing con-
clusions of class effects when the primary endpoints are not
significant. For example, in a trial of fluoxetine (an SSRI) in
constipation-predominant IBS, there was an unrepresenta-
tive 10 % placebo response for discomfort and bloating [28],
and, in a trial of 50 patients with diarrhea-predominant IBS,
amitriptyline, 10 mg, was uncharacteristically efficacious,
since 68 % of patients receiving this relatively low dose of
amitriptyline showed complete response defined as loss of
all symptoms, compared with only 28 % of those receiving
placebo [36]. In a third study of flexible dose of paroxetine,
there was no significant difference in the primary endpoint,
that is, the reduction of composite pain scores [37]. On the
other hand, meta-analyses often include the significant
effects on clinical global impression scores to illustrate
efficacy relative to placebo.
Moreover, the meta-analyses of antidepressants involve
relatively small total patient numbers. For example, one
meta-analysis [38] involved 13 studies that compared
antidepressants to placebo for treatment of IBS with a total
of 789 patients, 432 active therapy and 357 placebo. Sev-
eral analyses showed heterogeneity and even publication
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bias with Funnel plot asymmetry, thus raising important
flags that it is essential to cautiously interpret the results of
meta-analyses.
Regrettably, there are few trials involving patients with
IBS who were concomitantly suffering affective disorders
[39]. In those settings, including anxiety [40] and depres-
sion [39], psychoactive agents may be more effective.
Thus, in the systematic review of antidepressant agents in
patients with IBS and comorbid depression, there were 4
studies of SSRIs, 4 of TCAs, 1 of SSRI vs. TCA, and 1 of a
serotonin–norepinephrine reuptake inhibitor (duloxetine)
[41]. It is important to note that most studies excluded
patients with diagnosed depression and/or anxiety, and that
none of the controlled studies used the primary outcome of
assessment of the symptoms of manic-depressive disorder
in the IBS patients. The two SSRI studies (citalopram and
paroxetine) reported a statistically significant, *50 %,
improvement in IBS symptoms [24, 27]. Paroxetine also
provided an *30 % improvement in scores on Beck
Depression Inventory (also statistically significant) [27]. Of
two studies of fluoxetine, one (reviewed above) showed
benefit on IBS symptoms, though the 10 % response to
placebo for both pain and bloating seems uncharacteristi-
cally low. TCAs benefit IBS symptoms, predominantly
diarrhea, as expected. In addition, one of the TCA studies
found a significant improvement in depressive symptoms
with desipramine, 150 mg/day, (p = 0.025) [42].
Summary and conclusions
In conclusion, the effects of antidepressants on the gastroin-
testinal tract may contribute to their potential efficacy in
functional dyspepsia and IBS; buspirone appears efficacious
in functional dyspepsia. Clinical trials of antidepressants for
treatment of IBS are generally small. The recommendations
of efficacy and number needed to treat from meta-analyses are
suspect, and more prospective trials are needed. Additionally,
novel mechanisms such as effects on gut permeability and
immune dysregulation in IBS need to be explored.
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